12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga · 05/12 21:06
Gainers
- Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 28.6% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $48.6 million. As per the press release, Q1 earnings came out 2 days ago.
- OptimizeRx (NASDAQ:OPRX) shares rose 20.01% to $10.99. The market value of their outstanding shares is at $203.2 million. As per the press release, Q1 earnings came out today.
- NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 13.79% to $3.63. The company's market cap stands at $2.7 million.
- Passage Bio (NASDAQ:PASG) shares rose 10.28% to $0.34. The company's market cap stands at $21.1 million.
- Harvard Bioscience (NASDAQ:HBIO) shares increased by 10.13% to $0.39. The company's market cap stands at $17.1 million. As per the news, the Q1 earnings report came out today.
- Aspire Biopharma Hldgs (NASDAQ:ASBP) shares increased by 9.09% to $0.36. The market value of their outstanding shares is at $17.6 million.
Losers
- Polyrizon (NASDAQ:PLRZ) stock declined by 88.0% to $0.04 during Monday's after-market session.
- Hepion Pharmaceuticals (NASDAQ:HEPA) stock decreased by 33.28% to $0.21. The company's market cap stands at $2.3 million.
- Entero Therapeutics (NASDAQ:ENTO) shares fell 26.13% to $0.31. The company's market cap stands at $1.4 million.
- Accelerate Diagnostics (NASDAQ:AXDX) stock declined by 25.43% to $0.1. The company's market cap stands at $2.5 million.
- Sangamo Therapeutics (NASDAQ:SGMO) stock fell 15.36% to $0.63. The company's market cap stands at $142.0 million. As per the news, the Q1 earnings report came out today.
- Klotho Neurosciences (NASDAQ:KLTO) shares decreased by 10.06% to $0.16. The company's market cap stands at $4.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.